Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

Rumi, Elisa; Passamonti, Francesco; Elena, Chiara; Pietra, Daniela; Arcaini, Luca; Astori, Cesare; Zibellini, Silvia; Boveri, Emanuela; Pascutto, Cristiana; Lazzarino, Mario

doi:10.3324/haematol.2010.033779

Cited by 66 publications

(69 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 In a previous study 2 we reported that MPN patients have a 3.44-fold higher risk of lymphoid neoplasms compared with the general population, in line with current 1 and other results. 3 Considering nonhematologic cancers, Frederiksen et al reported a standardized incidence ratio (SIR) value of 1.2 (95% CI: 1.0-1.4) for essential thrombocythemia (ET) and 1.4 (95% CI: 1.3-1.5) for polycythemia vera (PV). 1 These estimates were based on 1578 ET and 4625 PV patients after a median follow-up of 4.0 and 5.0 years, respectively.…”

Section: Risk Of Second Cancers In Chronic Myeloproliferative Neoplasmsmentioning

confidence: 99%

“…Fallah et al reported an increased risk of kidney cancer, melanoma and nonmelanoma skin cancer, as well as endocrine cancers among patients diagnosed with polycythemia vera (PV). 3 Nielsen et al reported an increased risk of any cancer among JAK2 V617F mutation-positive persons from the general population. 4 In their study most new malignancies were CMPNs but also solid tumors were reported.…”

Section: Cancer Risk In Chronic Myeloproliferative Neoplasmsmentioning

confidence: 99%

See 1 more Smart Citation

Risk of second cancers in chronic myeloproliferative neoplasms

Susini

Masala

Antonioli

et al. 2012

Blood

View full text Add to dashboard Cite

Section: Risk Of Second Cancers In Chronic Myeloproliferative Neoplasmsmentioning

confidence: 99%

Section: Cancer Risk In Chronic Myeloproliferative Neoplasmsmentioning

confidence: 99%

Risk of second cancers in chronic myeloproliferative neoplasms

Susini

Masala

Antonioli

et al. 2012

Blood

View full text Add to dashboard Cite

“…However, with regard to the possible specific relationship between MPN and LNP, their association has been recently analyzed in two studies [1,4] that reported an increased risk of LPN in MPN patients with respect to the general population, with a 10-year risk of LPN in an MPN setting ranging from 0.7 [4] to 2.96% [1]. Of note, in both studies, the majority of patients first developed MPN with LPN as a secondary event.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, two studies have reported an increased risk of developing LPN in MPN patients [1,4], with a 10-year risk of LPN after onset of MPN ranging from 0.7 [4] to 2.96% [1]. …”

Section: Introductionmentioning

confidence: 99%

Development of JAK2V617F-Positive Polycythemia Vera after Chemotherapy-Induced Remission of Primary Central Nervous System Diffuse Large B Cell Non-Hodgkin's Lymphoma: A Case Report and Review of the Literature

Elli

Belotti²,

Cecchetti³

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

The coexistence or the development of Philadelphia chromosome-negative myeloproliferative neoplasms after a lymphoproliferative disease in the same patient is an extremely rare event. We report the case of a 72-year-old man who developed JAK2V617F polycythemia vera 3 years after the diagnosis and treatment of primary diffuse large B cell non-Hodgkin's lymphoma of the central nervous system. We also review the literature regarding the pathogenesis underlying the association of myeloproliferative and lymphoproliferative chronic disorders.

show abstract

“…It is uncertain whether there is a pathogenetic association between the myeloproliferative and lymphoproliferative diseases: It is likely that both are as a result of random mutations occurring in distinct initiating cells. However, given the higher risk of lymphoproliferative neoplasms development in myeloproliferative neoplasms reported in larger studies, the genomic instability characteristic to myeloproliferative neoplasms may contribute to subsequent lymphoproliferative neoplasms occurrence (29,30). The pathogenesis may be attributed to reduced immunocompetence and/or anti oncogene suppression.…”

mentioning

confidence: 90%

Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report

et al. 2015

View full text Add to dashboard Cite

Abstract.Myeloproliferative neoplasms are associated with lymphoproliferative diseases following the administration of cytotoxic drugs or exposure to radiation, but are rare prior to therapy. The present study reports the case of a 61-year-old female with a history of transient ischemic attack. The patient, who presented with a palpable mass in the epitrochlear area of the left arm, was simultaneously diagnosed with follicular lymphoma and an unclassifiable myeloproliferative neoplasm. Excisional lymph node biopsy revealed stage I follicular lymphoma (grade 1). Laboratory findings demonstrated leukocytosis, erythrocytosis, thrombocytosis and decreased erythropoietin. Biopsy of the bone marrow revealed hypercellularity, with predominance of erythroid cells, and large polylobated megakaryocytes with increased mitotic figures, but no evidence of lymphomatous infiltration. The janus kinase 2 V617F mutation was also detected in the cells derived from the bone marrow specimen. Following local excision of the lymph node in the left epitrochlear area, radiation was delivered to the involved field, at a dose of 24 Gy in 12 fractions. The patient was started on hydroxyurea (1 g twice per day, orally) 2 weeks subsequent to radiotherapy, and was administered 500 mg twice per day as maintenance therapy. At the six-month follow-up, the white blood cell count, hemoglobin levels and platelet count had reduced, and the patient was in a healthy condition. A computed tomography scan of the neck, chest and abdomen indicated no abnormalities. To the best of our knowledge, the present study is the first case report of follicular lymphoma coexisting with an unclassifiable myeloproliferative neoplasm in a previously healthy patient. Molecular and genetic studies are required to further evaluate this infrequent disease association.

show abstract

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

Cited by 66 publications

References 21 publications

Risk of second cancers in chronic myeloproliferative neoplasms

Risk of second cancers in chronic myeloproliferative neoplasms

Development of JAK2V617F-Positive Polycythemia Vera after Chemotherapy-Induced Remission of Primary Central Nervous System Diffuse Large B Cell Non-Hodgkin's Lymphoma: A Case Report and Review of the Literature

Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report

Contact Info

Product

Resources

About